Cargando…
Expression of Concern: Antitumor Activity of Sorafenib in Human Cancer Cell Lines with Acquired Resistance to EGFR and VEGFR Tyrosine Kinase Inhibitors
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
Public Library of Science
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6459487/ https://www.ncbi.nlm.nih.gov/pubmed/30973909 http://dx.doi.org/10.1371/journal.pone.0215109 |
Ejemplares similares
-
Expression of Concern to: Randomized Trial of First-Line Tyrosine Kinase
Inhibitor With or Without Radiotherapy for Synchronous Oligometastatic
EGFR-Mutated Non-Small Cell Lung Cancer
Publicado: (2022) -
Antitumor Activity of Sorafenib in Human Cancer Cell Lines with Acquired Resistance to EGFR and VEGFR Tyrosine Kinase Inhibitors
por: Morgillo, Floriana, et al.
Publicado: (2011) -
Expression of Concern: Autophagosome-Mediated EGFR Down-Regulation Induced by the CK2 Inhibitor Enhances the Efficacy of EGFR-TKI on EGFR-Mutant Lung Cancer Cells with Resistance by T790M
Publicado: (2019) -
Expression of Concern. EGFR Tyrosine Kinase Inhibitor (PD153035) Improves
Glucose Tolerance and Insulin Action in High-Fat Diet–Fed Mice. Diabetes
2009;58:2910–2919. DOI: 10.2337/db08-0506. PMID: 19696185
por: Prada, Patricia O., et al.
Publicado: (2017) -
Expression of Concern: ACKR4 restrains antitumor immunity by regulating CCL21
Publicado: (2023)